74%
jaeinvestorite kontodest jääb selle teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse.
Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. CFD-d on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti.
74%
jaeinvestorite kontodest jääb selle teenusepakkuja juures CFD-dega kauplemisel kahjumisse.
Palume teil kaaluda, kas CFD-de toimimine on teile arusaadav ja kas te olete valmis võtma riski, mis suure tõenäosusega on kahjumlik.
74%
jaeinvestorite kontodest jääb selle teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse.
Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. CFD-d on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti.
74%
jaeinvestorite kontodest jääb selle teenusepakkuja juures CFD-dega kauplemisel kahjumisse.
Palume teil kaaluda, kas CFD-de toimimine on teile arusaadav ja kas te olete valmis võtma riski, mis suure tõenäosusega on kahjumlik.
Haemonetics Corp
Suletud
SektorTervishoid
51.15 -0.29
Ülevaade
Aktsiahinna muutus
24h
Min
51.15
Max
51.42
Sissetulek | -24M 34M |
|---|---|
Müük | -9.2M 321M |
P/E Sektori keskmine | 15.367 37.461 |
Aktsiakasum | 1.1 |
Kasumimarginaal | 10.589 |
Töötajad | 3,023 |
EBITDA | 6.7M 78M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +42.66% upside |
Järgmine tulemuste avaldamine | 6. nov 2025 |
|---|
Turukapital | -1.2B 2.4B |
|---|---|
Eelmine avamishind | 51.44 |
Eelmine sulgemishind | 51.15 |
Uudiste sentiment
By Acuity
50%
50%
147 / 371 Pingereas Healthcare
Tehniline skoor
By Trading Central
Kindlus
Strong Bullish Evidence
Haemonetics Corp Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Haemonetics Corp Prognoos
Hinnasiht
By TipRanks
42.66% tõus
12 kuu keskmine prognoos
Keskmine 73.13 USD 42.66%
Kõrge 86 USD
Madal 62 USD
Põhineb 9 Wall Streeti analüütiku instrumendi Haemonetics Corp 12 kuu hinnasihil - viimase 3 kuu andmed.
Sentiment
By Acuity
147 / 371 Pingereas Tervishoid
Uudiste sentiment
Neutral
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Haemonetics Corp
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Live chat